Atlas Trials

Phase I Study to Evaluate the Safety and Efficacy of Telomelysin (OBP-301) in Patients With Hepatocellular Carcinoma

Clinical trial NCT02293850 · UNKNOWN

Trial details

NCT number
NCT02293850
Sponsor
Oncolys BioPharma Inc
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
Carcinoma, Hepatocellular
Start date
2014-10-01
Primary completion
2019-04-01
Enrollment
18

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.